Investor Centre
Investor Highlights
Half Year Report - 31 December 2018
Pharmaxis Ltd financial and directors' reports for the six months ended 31 December 2018
Read report – pdfShareholder Update - December 2018
Shareholder update for the quarter ended 31 December 2018
Read quarterly update - pdfPharmaxis Announces LOXL2 Inhibitor Program is Phase 2 Ready Following Completion of 13 Week Toxicity Studies
Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that it has now received reports on all of the 13-week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors. Together with the previously released results of Pharmaxis phase 1 clinical trials for both compounds showing best in class target engagement from a once a day oral dose, Pharmaxis believes that this program is now ready to enter phase 2 clinical studies for fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH), cardiac fibrosis and Idiopathic Pulmonary Fibrosis (IPF).
Read full media release - pdfCEO Presentation to 2018 AGM
Presentation by the Pharmaxis CEO and CFO to the 2018 AGM
View presentation – pdf2018 Annual Report
2018 Statutory Annual Report
Read report – pdf